Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/175330
Title: Angiotensin AT1 and AT2 receptors heteromer expression in microglia correlates with Parkinson's disease progression in the hemilesioned rat model of the disease
Author: Rivas Santisteban, Rafael
Rodríguez Pérez, Ana I.
Muñoz, Ana
Reyes-Resina, Irene
Labandeira García, José L.
Navarro Brugal, Gemma
Franco Fernández, Rafael
Keywords: Receptors cel·lulars
Malaltia de Parkinson
Malalties neurodegeneratives
Cell receptors
Parkinson's disease
Neurodegenerative Diseases
Issue Date: 1-Feb-2020
Publisher: Karger
Abstract: Background/Aims : The renin-angiotensin system (RAS) is altered in Parkinson's disease (PD), a disease due to substantia nigra neurodegeneration and whose dopamine-replacement therapy, using the precursor levodopa, leads to dyskinesias as the main side effect. Angiotensin AT 1 and AT 2 receptors, mainly known for their role in regulating water homeostasis and blood pressure and able to form heterodimers (AT 1/2 Hets), are present in the central nervous system. We assessed the functionality and expression of AT 1/2 Hets in Parkinson Disease (PD). Methods: Immunocytochemistry was used to analyze the colocalization between angiotensin receptors, bioluminescence resonance energy transfer was used to detect AT 1/2 Hets. Calcium and cAMP determination, MAPK activation and label-free assays were performed to characterize signaling. Proximity ligation assays was used to quantify receptor expression in microglial cells and brain striatal slices. Results: We confirmed that AT 1 and AT 2 receptors form AT 1/2 Hets that are expressed in cells of the central nervous system. AT 1/2 Hets are novel functional units with particular signaling properties. Importantly, the coactivation of the two receptors in the heteromer reduces the signaling output of angiotensin. Remarkably, AT 1/2 Hets that are expressed in both striatal neurons and microglia show a cross-potentiation, i.e. candesartan, the antagonist of AT 1 increases the effect of AT 2 receptor agonists. In addition, the level of expression in the unilateral 6-OH-dopamine lesion rat PD model increases upon disease progression and is maximal in dyskinetic animals. Conclusion: The results indicate that boosting the action of neuroprotective AT 2 receptors using an AT 1 receptor antagonist constitutes a promising therapeutic strategy in PD.
Note: Reproducció del document publicat a:
It is part of: Cellular Physiology and Biochemistry, 2020
URI: http://hdl.handle.net/2445/175330
ISSN: 1015-8987
Appears in Collections:Articles publicats en revistes (Bioquímica i Biomedicina Molecular)
Articles publicats en revistes (Bioquímica i Fisiologia)

Files in This Item:
File Description SizeFormat 
699979.pdf535.42 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons